BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28

• 

  Magenta Cuts 5 Executives, 84% of Staff Following Patient Death

  Magenta Therapeutics is cutting about 84% of its workforce after a patient’s death halted a Phase I/II trial in acute myeloid leukemia.

  February 3, 2023

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug Development

  Merck Eyes Third Endometrial Cancer Nod for Keytruda

  Keytruda could be on its way to snagging another indication as a first-line therapy for endometrial cancer after the company announced positive Phase III results Friday.

  February 3, 2023

   · 

  1 min read

   · 

  Hayley Shasteen
• 

  Drug Development

  Novel Biomarkers could Guide New Alzheimer’s Therapies

  The discovery of novel Alzheimer’s biomarkers is enabling better trial selection, earlier pipeline decision making and new targets for therapeutics.

  February 3, 2023

   · 

  4 min read

   · 

  Kate Goodwin
• 

  Drug Development

  Sanofi Admits Defeat for Myasthenia Gravis Candidate, Drops Phase III Trial

  Sanofi is discontinuing its Phase III study of tolebrutinib, an investigational BTK inhibitor for myasthenia gravis.

  February 3, 2023

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Unphased by Bear Market, Structure Goes Big with $161.1M IPO

  Structure Therapeutics expects to bring in $161.1 million from an upsized IPO, announced Friday.

  February 3, 2023

   · 

  1 min read

   · 

  Kate Goodwin
• BioCapital

  Orexo submits New Drug Application to FDA for OX124, a high-dose rescue medication for opioid overdose

  Orexo AB, announces the submission of a New Drug Application to the US Food and Drug Administration for its lead pharmaceutical pipeline asset, OX124, a nasal rescue medication for opioid overdose.

  February 3, 2023

   · 

  4 min read
• Microbion Corporation CEO to Present at the 2023 BIO CEO & Investor Conference

  Microbion Corporation, a clinical stage pharmaceutical company, announced that Karim Lalji, CEO of Microbion Pharma Corp., will be presenting at the 2023 BIO CEO & Investor Conference in New York, NY.

  February 3, 2023

   · 

  2 min read
• Midatech Pharma PLC Announces Receipt of NASDAQ Notice - February 03, 2023

  Midatech Pharma PLC announces that it received written notification from The NASDAQ Stock Market LLC, dated 31 January 2023, stating that the Company is not in compliance with the minimum bid price requirement set forth in NASDAQ’s rules for continued listing on The NASDAQ Capital Market.

  February 3, 2023

   · 

  6 min read
• Business

  Cigna Reports Strong Fourth Quarter and Full Year 2022 Results, Establishes 2023 Guidance and Increases Dividend

  Global health services company Cigna Corporation reported strong 2022 results reflecting growth in both Evernorth and Cigna Healthcare.

  February 3, 2023

   · 

  26 min read
• Genetown

  KalVista Pharmaceuticals to Present at SVB Securities Global Biopharma Conference

  KalVista Pharmaceuticals, Inc. today announced it will be presenting at the SVB Securities Global Biopharma Conference (virtual) on Thursday, February 16, 2023 at 8:40 a.m. ET.

  February 3, 2023

   · 

  2 min read